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Replication
Fibrosisicated that hepatitis B virus genotype G (HBV/G) is present exclusively in
coinfection with other HBV genotypes. In Mexico, HBV/G from 6 men who had sex with men were coinfected
with HBV/H. Phylogenetically complete genomes of the 6 Mexican HBV/G strains were closely related to
previous ones from the US/Europe. Using uPA/SCID mice with human hepatocytes, monoinfection with HBV/
G did not result in detectable HBV DNA in serum, whereas superinfection with HBV/G at week 10 inoculated
HBV/H when HBV/H DNA was elevated to N107 copies/mL has enhanced the replication of HBV/G. The HBV/G
was enhanced in another 3 inoculated with a serum passage containing HBV/G with a trace of HBV/H.
Coinfection of mice with HBV/G and H induced ﬁbrosis in the liver. In conclusion, the replication of HBV/G
can be enhanced remarkably when it is coinfected with HBV/H. Coinfection with HBV/G may be directly
cytopathic in immunosuppressive conditions.
© 2008 Elsevier Inc. All rights reserved.Introduction
On the basis of the nucleotide sequence divergence exceeding 8%
throughout the complete genome sequence, hepatitis B virus (HBV)
has been classiﬁed into eight genotypes designated by capital letters A
(HBV/A) through H (HBV/H) (Arauz-Ruiz et al., 2002; Norder et al.,
1994; Okamoto et al., 1988; Stuyver et al., 2000). The genotypes have
different geographical distributions, virological characteristics and
clinical manifestations (Magnius and Norder, 1995; Miyakawa and
Mizokami, 2003).
One of the less studied genotypes is the HBV/G. It was ﬁrst
described in 2000, among inhabitants of France and Georgia, USA
(Stuyver et al., 2000). The isolated strains had 36 base-pairs' insertionis B e antigen; HBsAg, hepatitis
e; uPA/SCID, severe combined
minogen activator.
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l rights reserved.in the core gene and two stop codons in the precore region depriving
ability of the virus to translate HBeAg. Nevertheless, some of the
carriers were HBeAg positive (Stuyver et al., 2000) that was shortly
after explained by the coexistence of the “HBeAg-potent” HBV/A
strains in coinfection (Kato et al., 2002a,b). Further studies reported
circulation of the genotype in Thailand (Suwannakarn et al., 2005),
Japan (Ozasa et al., 2006) and Mexico (Sanchez et al., 2007) indicating
global distribution and association of the infection with speciﬁc risk
groups, such as injection drug users (IDU) and men who had sex with
men (MSM). The studies also demonstrated that throughout theworld
HBV/G strains possess unprecedented genetic homology and are
mainly presented in coinfection with another endemic genotype.
However, little is known about peculiarities of interaction of the HBV/
G with various genotypes as well as about virological and clinical
concerns of the coinfection.
Produced by genetic engineering, a mouse with severe combined
immunodeﬁciency, carrying urokinase-type plasminogen activator
transgenes controlled by albumin promoter (uPA/SCID) with trans-
planted human hepatocytes (Heckel et al., 1990; Rhim et al., 1994)
was recently shown as an appropriate animal model for studying
HBV (Dandri et al., 2001; Tsuge et al., 2005). Using this model
it was demonstrated that during monoinfection, HBV/G might be
able to replicate in hepatocytes at low level; but its replication was
Fig. 1. A phylogenetic tree constructed using the complete nucleotide sequences of 50
HBV strains. The 6 HBV/G strains coinfected with HBV/H in Mexico (MEX), shown in
bold italic, were compared with reference sequences recruited from GenBank/DDBJ/
EMBL databases; 10 HBV/G, 7 HBV/H, 13 HBV/F, 7 representing genotypes A–E and 1
outgroup (Wolly Monkey). Aa and Ae are subgenotypes of HBV/A (Sugauchi et al., 2004).
Ba and Bj are subgenotypes of HBV/B (Sugauchi et al., 2002). The country of origin is
indicated after the accession number for each HBV/F, HBV/H and HBV/G strain.
Bootstrap values are shown at the nodes of the main branches.
409Y. Tanaka et al. / Virology 376 (2008) 408–415signiﬁcantly enhanced by coinfection with HBV/A or C (Sugiyama
et al., 2007).
Our purpose is to determine the complete sequences of HBV/G
coinfected with HBV/H in sera obtained from MSM in Mexico and to
elucidate the characteristics of HBV/G in coinfectionwith HBV/H using
recently developed in vivo model.
Results
Phylogenetic relatedness of HBV complete genome sequences in Mexico
Six HBV/G strains in coinfection with HBV/H among MSM in
Mexico were described in our previous study (Sanchez et al., 2007). In
the present study, the complete genome sequences of not only 6 HBV/
G strains but also 6 HBV/H strains from the same patients were
determined by each speciﬁc PCR. The phylogenetic analyses indicated
that the 6 HBV/G strains were close to those previously reported from
the United States (US), France and Germany, and the 6 HBV/H strains
were related to the previously reported ones in the US (Fig. 1). All 6
coinfected patients were positive for HBeAg, and asymptomatic
carriers of chronic HBV infection at the time of sample collection
(the details unknown).
Characteristics of HBV/G strains in Mexico
Sequence analyses revealed unique insertion of 36 nt in the core
gene, two stop codons in the precore region and double mutation in
the core promoter (CP) in all Mexican HBV/G strains, whereas no
related mutations were found in the corresponding HBV/H strains
(Fig. 2a and b). These data suggest that the HBeAg detected in serum of
those patients had been produced by HBV/H. Additionally, several
mutations, which might have affected the replication of the virus
genomeand amino acid substitutions of HBx,were found in theﬁrst half
of the CP region, including the above double mutation (nt 1701–1765)
(Fig. 2a).
Examining the genetic diversity and recombination of HBV/G
Comparing the complete sequences, both overall genetic distance
among the HBV/G strains (0.0037±0.0005 per site) and percent
nucleotide homology (0.30±0.24%) were much lower than those
among the other intra-genotype groups. In consideration of pre-
viously reported recombination between HBV/A and HBV/G strains
(i.e. AB056516) (Kato et al., 2002a), we have examined the Mexican
HBV/G strains for possible event of intergenotypic recombination.
Complete sequences of 3 to 5 clones isolated from each of the 6 HBV/G
carriers revealed; no evidence of recombination by similarity and
bootstrap scan (data not shown).
Intracellular expression of HBV DNA and antigens
Huh7 cells were transfected with a pUC19 vector carrying 1.24-fold
the HBV genome. Three days post-transfection, they were harvested,
lysed with NP-40 and tested for HBV DNA and antigens. The density of
single-stranded (ss) HBVDNAwas compared between HBV/G andH by
Southern blotting. The expression of HBV DNA was higher for HBV/H
than G, indicating that HBV/G had very low replication in vitro (Fig. 3a).
As well, HBsAg, HBeAg and HBcrAg levels were much higher in HBV/H
(Fig. 3b).
Superinfection with HBV/G on mice infected with HBV/H
Chimeric mice were infected with HBV/G and H particles prop-
agated in Huh7 cells in order to conﬁrm the infective efﬁciency.
Monoinfection with HBV/G from the Huh7 cells culture medium did
not result in detectable HBV DNA in mice serum (data not shown).Then, according to our previous method (Sugiyama et al., 2007),
the dynamics of HBV DNA, HBsAg and HBeAg assessed in 3 chimeric
mice (ChiM_H1–H3) with HBV/G on H superinfection, are shown in
Fig. 4 (a–c). Initially each of the mice received inoculation of around
105 copies of HBV/H recovered from the Huh7 cells culture super-
natants, and the dynamics of HBV/H DNA indicated approximately
2 logs elevation within the following 5 weeks. At week 10 when
HBV/H DNA level exceeded concentration of N107 copies/mL, the
chimeric mice were superinfected by inoculation of HBV/G. The
HBV/G DNA level increased within 5 weeks after the superinfection
and plateaued around 107 copies/mL. Two HBV antigens (HBsAg
and HBeAg) waxed and waned in proﬁles similar to that of HBV
DNA.
Fig. 2. Nucleotide sequences spanning (a) core promoter and (b) precore gene in HBV genotypes A–H. The reference sequence is shown for the AB014370Ae. The precore region
includes pregenome encapsidation signal. Positions of the double mutation (A1762Tand G1764A), T1753C, and C1858Tmaking a pair with G1896A are indicated by inverted triangles.
Two stop codons in the precore region are shaded.
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Fig. 3. Intracellular expression of HBV DNA and antigens. (a) The density of single-
stranded (ss) HBV DNA was compared between HBV/G and H by Southern blotting. RC;
relaxed circular double stranded DNA forms. (b) HBsAg, HBeAg and HBcrAg levels were
also compared.
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passage of G-on-H superinfection
Another3 chimericmice (ChiM202-17, ChiM212-22andChiM314-12)
received serum from sacriﬁced ChiM_H2 with G-on-H superinfection
taken at week 34 when the HBV/G and H DNA was around 5×106, 108
copies/mL, respectively (Fig. 4b). Proﬁles of HBV/H and G, after inoc-
ulationwith 106 copies of HBV DNA, were similar among the 3 chimeric
mice. Despite receiving the inoculationwith amousepassage supposedly
containingHBV/G strain, theHBV/GDNAwasnot detectable until week 4
after the passage. At the week 4 when HBV/H DNA level exceeded
concentration of N107 copies/mL, HBV/G started to increase and
plateaued around 108 copies/mL at week 16 (Fig. 4d).
Cloning and sequencing HBV DNA in chimeric mice coinfected with HBV/
H and G
HBVDNA clones from sera of the ChiM_H1 and ChiM_H2 sampled at
26 and 34 weeks, respectively (Fig. 4a and b) included those of HBV/H
and G invariably. At least 5 clones were propagated and completely
sequenced in each serum; but no mutation was observed when the
clones were compared to the original inoculum of either genotype. No
evidence of recombinations was detected between HBV/H and G on the
basis of complete genome analyses.
Pathology in the liver of chimeric mouse infected with HBV/G and H
Fig. 5a shows histology of liver of a chimeric mouse 26 weeks after
superinfection with HBV/G on H (ChiM_H1). The mouse coinfected
with HBV/G andH revealed ﬁbrosis of stage 1 (F1) and inﬂammation of
grade 2 (A2) with Hematoxlin–Eosin and Masson's trichrome stain
(Fig. 5a), whereas the mouse monoinfected with HBV/H had no
ﬁbrosis (Fig. 5b). ChiM_H2 also had F1A1 at week 34, but ChiM_H3
was not available for histological examination due to sudden death.Interestingly, a chimeric mouse (ChiM202-17) received serum from
ChiM_H2 with G-on-H superinfection revealed F2A2 at week 24
(Fig. 5c). It might be difﬁcult to evaluate its statistical signiﬁcance due
to small number.
Discussion
The HBV/G was initially reported in the US, Canada and Europe in
coinfection with HBV/A (Kato et al., 2002a,b; Osiowy and Giles, 2003;
Stuyver et al., 2000), which is the one of the prevalent genotypes in both
of the regions. Recently, coinfection of HBV/G with H as well as G/C
recombinant were reported in Mexico and Thailand, respectively
(Sanchez et al., 2002, 2007; Suwannakarn et al., 2005), and accumulated
data indicated trend to preferential occurrence of the HBV/G coinfection
in population of MSM and IDU, possibly via particular infectious routes
of transmission. A phylogenetic analysis of the complete genome of
HBV/G strains isolated in the present study indicated their close
relationship with those previously reported, despite the fact that they
were all isolated from HBV carriers infected with different genotypes
thatwere prevalent in the respective area. These suggest that theHBV/G
is genetically homologous and has no speciﬁc preference for HBV
genotype to be coinfected. Thus, the HBV/G may be found among HBV
carriers in any part of the world regardless of the prevalent genotype.
Invariably coinfectedwith other genotypes,HBV/Gwasoncedeemed
adefective virus that cannot replicate by itself. Recently, however, Chudy
and his associates reported plasmapheresis and platelet donor whowas
infected with HBV/G alone and had transmitted it to two recipients in
look-back studies (Chudy et al., 2006). Since the donor and two
recipients were not coinfected with HBV of the other genotypes by the
reversed hybridization assay (Hussain et al., 2003), capable of detecting
HBV infection of any genotype in low titers, the authors concluded that
HBV/G can monoinfect human beings without help from coinfecting
HBV of other genotypes (Chudy et al., 2006).
The uPA/SCID mouse with the liver replaced for human hepato-
cytes (Heckel et al., 1990) is a very usefulmodel for studies on hepatitis
virus infection and replication in vivo (Dandri et al., 2001; Tsuge et al.,
2005). Using this model we have previously demonstrated that
despite of apparent dependence on other genotype strain (HBV/A or
HBV/C) in replication, the viral load of the HBV/G eventually outgrows
and takes over the coinfecting strain in the chimeric mice (Sugiyama
et al., 2007).
In the present study, the chimeric mice had undetectable HBV DNA
in the serumwhenmonoinfected with HBV/G, whereas superinfection
on HBV/H enhanced replication of the HBV/G. This observation is
concordant with previous experimental study which indicated a rapid
takeover in mice initially infected with HBV/A or C and superinfected
with HBV/G (Sugiyama et al., 2007). The takeover was signiﬁcantly
enhanced in mice infected with HBV/G on HBV/A when compared to
HBV/G on HBV/C; with the mean time required for a 10-fold increase
(log time) in the HBV/DNA level 1.6 vs. 3.3 weeks, respectively
(Sugiyama et al., 2007). Interestingly, the present study demonstrates
that pattern of the genotypic interaction between HBV/G and H was
similar to that described for HBV/G on C; with the HBV DNA log time
3.0 weeks, suggesting that HBV/G is better sustained in human
population by its association with HBV/A than with other HBV
genotypes. These experimental results were also supported by clinical
observations of the takeover which was demonstrated in a patient
coinfected with HBV/G and A by cloning and sequencing (Kato et al.,
2002a). However, such a heavy dependence of HBV/G on other
genotype strain does not seem to require intergenotypic recombina-
tion between them, as no recombination event was observed in
chimeric mice coinfected with HBV/G and any other genotype strain.
The mechanism how HBV/G depends on other genotypes for
replication had been pursued in cotransfection experiments in Huh7
cells; our previous in vitro study showed that trans-complementation
with core protein of HBV/A would be required for HBV/G to replicate
Fig. 4. Superinfection with HBV/G on chimeric mice infected with HBV/H [(a) ChiM_H1, (b) ChiM_H2, (c) ChiM_H3]. Inoculation with genotype G is indicated by large arrows. The
dynamics of HBV DNA, HBsAg and HBeAg assessed superinfection of 3 chimeric mice (ChiM_H1–H3) are shown in panels a–c. Another 3 chimeric mice received serum from ChiM_H2
with G-on-H superinfection taken at week 34when HBV/G DNA plateaued around 107 copies/mL (Fig. 4b). Proﬁles of HBV/H and G, after inoculationwith 106 copies of HBV DNA, were
similar among the 3 chimeric mice. Mean HBV DNA and standard deviation (bar) were shown in panel d.
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HBV/G might be also enhanced by core protein of HBV/H. Two other
functional analyses of HBV/G had been already reported. Kremsdorf et
al. have proposed the involvement of polymerase encoded by HBV/G
in active replication (Kremsdorf et al., 1996) and Li et al. showed that
lack of HBeAg expression rather than a replication defect could be the
primary determinant for the rare occurrence of HBV/G monoinfection
(Li et al., 2007). Hence, possibility remains for other viral elements
beyond core protein from coinfecting genotypes to enhance the
replication of HBV/G. Further studies are needed to elucidate the
mechanism of HBV/G replication by cotransfection of other proteins
beyond core protein of HBV/H or construction of domain-switch
experiments between the genome of HBV/G and H.
Considering that coinfection with HBV/G may be associated with
pathological manifestations, liver histology was investigated in tissue
obtained from the mice used in this study. The chimeric mouse co-infected with HBV/G and H had developed ﬁbrosis and inﬂammation
(F1–2, A1–2) in the liver thatwas not observed inmicewith HBV/G or H
monoinfection. This might be supported by clinical data in Mexico;
Mexican patients infected with the most prevalent HBV/H have milder
liver damagewhen it is inmonoinfection rather than in coinfectionwith
other genotypes (personal communication). Our recent study also
showed ﬁbrosis of F1–F2 stage in themajority of themice superinfected
withHBV/GonAorC (Sugiyamaet al., 2007). Clinically, Lacombeandher
colleagues reported more severe ﬁbrosis in human immunodeﬁciency
type-1 (HIV)-positive French patients who were infected with HBV/G
than the others (Lacombe et al., 2006). Taken together, clinical and
experimental observations indicate that in immunodefﬁcient conditions
HBV/G possesses stronger disease-inducing capacity when it is
coinfected with other genotype. Unfortunately, studied patients did
not have exact diagnosis due to neither histopathological examination
nor abdominal ultrasonography, although they were asymptomatic.
Fig. 5. Liver histology in chimeric mice superinfected with HBV/G on H. (a) A chimeric
mouse 26 weeks after superinfection with HBV/G on H (ChiM_H1) revealed F1A2 with
Hematoxlin–Eosin (HE) and Masson's trichrome stain. (b) A chimeric mouse 24 weeks
after monoinfection with HBV/H had no ﬁbrosis. The peak of HBV DNA was around 108
copies/mL. (c) Another chimeric mouse (ChiM202-17) received serum from ChiM_H2
with G-on-H superinfection revealed F2A2 at week 24.
Table 1
HBV DNA oligonucleotide primers for complete genomes of genotype G
Primer Nucleotide sequence (5′–3′) Position⁎ Polarity
1) Fragment A
HBVG3157F CCTCCTGCCTCCACCAATCG 3157–3176 Sense
HBVG1917R AGCCAAAAAGGCCATATGGCA 1937–1917 Antisense
HBVG3187F AGGCAGCCTACTCCCATCTC 3187–3206 Sense
HBVG1797R CATGGTGCTGGTGCGCAGAC 1816–1797 Antisense
2) Fragment B
HBVG1601F ACGTTACATGGAAACCGCCA 1601–1620 Sense
HBVG103R GATTGACGAGATGTGAGAGGCA 124–103 Antisense
HBVG1630F CTCATCATCTGCCAAGGCAGT 1630–1650 Sense
HBVG56R GAACTGGAGCCACCAGCAGG 75–56 Antisense
3) Sequencing primers
HBSF2 CTTCATCCTGCTGCTATGCCT 407–426 Sense
HBVG894F AAGTTGGGGTACTTTGCCAC 894–913 Sense
HBVG1013R TGGGTAAAAGGAGCAGCGAAAC 1034–1013 Antisense
HBVG2052F GGGAATCCTTAGAGTCCTCTG 2052–2072 Sense
HBVG2491F TTCCTTGGACTCACAAGGTG2 2491–2510 Sense
⁎ Nucleotide position of reference sequence (AB056513).
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DNA levels (viral replication) and/or other factors would affect liver
ﬁbrosis in immunosuppressive conditions.
Two remarkable viral genomic characteristics of the HBV/G have
been established by previous reports; one of them is the unique
insertion of 36 bp in the core gene, which is shared by all HBV/G strains
studied herein and previously (Fig. 2). Although screening of the entire
DNA Genome Bank (BLAST search) did not reveal any homologous to
the insertion parts within other sequences including those of human,
we took the advantage of these peculiar insertion sequences for
designing the type-speciﬁc primers to be used for screening (Kato
et al., 2001) and quantiﬁcation of the genotype (Sugiyama et al., 2007).
In respect to the function of this insertion, it may inducemodiﬁcations
of both the encapsidation signal sequence and the core protein
structure, as previously proposed (Junker-Niepmann et al., 1990).
Furthermore, HBV/G strains include two stop codons in the precore
region at positions 2 and 28, both of which prohibit the translation of
the HBeAg precursor (Carman et al., 1989; Okamoto et al., 1990),
assumably resulting in HBeAg-negative phenotype of all HBV/G
strains. In this study all patients infected with HBV/G, however, were
positive for HBeAg. The coinfection with HBV/H would explain the
presence of HBeAg in individuals infectedwithHBV/G,whichwould be
consistent with a previous report (Kato et al., 2002a).In conclusion, the replication of HBV/G can be enhanced
remarkably when it is coinfected with HBV/H prevalent in Mexico.
Coinfection with HBV/G may be directly cytopathic in immuno-
suppressive conditions. Further epidemiological, clinical and in vitro
studies are required to conﬁrm the clinical manifestation of the
HBV/G coinfection with various genotypes and evaluate its geno-
typic peculiarities.
Methods
Serum samples
Nineteen HBsAg-positive sera were obtained from previously
described MSM cohort (age range 22–30 years) in Mexico (Sanchez
et al., 2007). HBeAg was detected with chemiluminescent enzyme
immunoassay (Ortho Clinical Diagnostics, Tokyo, Japan).
Determination of HBV genotypes and the complete sequences of HBV
Initially, HBV genotypes were determined by EIA with monoclonal
antibodies directed to the preS2 epitopes (Usuda et al., 1999, 2000),
with use of commercial kits (HBV GENOTYPE EIA, Institute of
Immunology Co., Ltd., Tokyo, Japan), allowing the determination of
HBV/A–F and HBV/H. HBV/Gwas conﬁrmed by the G-speciﬁc PCRwith
one of the primers deduced from the sequence of 36 nt. insertion in
the core gene (Kato et al., 2001). The complete genomes were further
determined. In brief, two partially overlapping fragments were
ampliﬁed by nested PCR using two sets of primers with LA Taq
(TaKaRa Bio Inc., Tokyo, Japan) (Table 1). Similarly, the complete
genomes of HBV/H strains were also ampliﬁed as two overlapping
fragments using different set of primers shown in the Table 2.
Thereafter, the PCR products were cloned in a plasmid pGEM-T easy
vector (Promega Corp., Madison, WI, US) and sequenced using
sequencing primers (Tables 1 and 2) with Prism Big Dye (Applied
Biosystems, Foster City, CA, US) on the ABI 3100 DNA automated
sequencer. Reference sequences for comparative analyses were
retrieved from the DDBJ/EMBL/GenBank database.
Plasmid constructs of HBV DNA
HBV DNA from a Mexican patient (MEX33) was extracted from
100 μL of serum using the QIAamp DNA blood kit (QIAGEN, GmbH,
Hilden, Germany). Two overlapping fragments, fragment A and
fragment B approximately 1700 bp long, covering the entire genome
Table 2
HBV DNA oligonucleotide primers for complete genomes of genotype H
Primer Nucleotide sequence (5′–3′) Position Polarity
1) Fragment A
HBVH55F TCCTGCTGGTGGCTCC 55–70 Sense
HBVH1801R GTTGCATGGTGCTGGTGAAC 1820–1801 Antisense
HB6R AACAGACCAATTTATGCCTA 1803–1784 Antisense
2) Fragment B
HBVH1611F GAGACCACCGTGAACGCCC 1611–1629 Sense
HBVH285R GCCAGGACACCCGGGTGGTA 304–285 Antisense
HBVH229R CGAGTCTAGACTCTGTGGTATTGTGAGG 256–229 Antisense
3) Sequencing primers
HB2F TGCTGCTATGCCTCATCTTC 414–433 Sense
HBVH760F GCCAAATCTGTGCAGCATCTTGAG 760–783 Sense
HB5F CTCTGCCGATCCATACTGCGGAA 1256–1278 Sense
HBVH1859F ACTGTTCAAGCCTCCAAGCTGT 1859–1880 Sense
HBVH2415F GTCGCAGAAGATCTCAATCTC 2415–2435 Sense
HBVH2814F GGGTCACCATATTCCTGGGAA 2814–2834 Sense
⁎Nucleotide position of reference sequence (AB059659).
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Table 2). Primers used for fragment Awere HBVH55F and HBVH1801R
for 1st PCR and HBVH55F and HB6R for 2nd PCR. Primers used for
fragment B were HBVH1611F and HBVH285R for 1st PCR and
HBVH1611F and HBVH229R for 2nd PCR. Then these fragments were
ligated into pGEM-T vector (Promega, Madison, WI) and cloned in
DH5α cells. Ten clones each (pGEM-fragA-1 to 10, pGEM-fragB-1 to
10) were obtained and the nucleotide sequences were determined. As
reported previously (Fujiwara et al., 2005; Sugiyama et al., 2006),
these fragments were constructed into the pUC19 vector deprived of
promoters (Invitrogen Corp., Carlsbad, CA) by digestion with HindIII
and EcoRI, resulting in 1.24-fold the HBV genome, just enough to
transcribe over-sized pregenome and precoremRNA. Cloned HBV DNA
sequences were determined with Prism Big Dye (Applied Biosystems,
Foster City, CA) in the ABI 3100 automated sequencer. Based on our
previous report (Sugiyama et al., 2007), a plasmid of HBV/G with 1.24-
fold the HBV genome was also constructed in this study.
Cell culture and transfection
Huh7 cells were transfected with plasmids equivalent to 5 μg of
HBV DNA constructs with use of the Fugene 6 transfection reagent
(Roche Diagnostics, Indianapolis, IN), and harvested after 3 days in
culture. Transfection efﬁciency was monitored by enzymatic activity
of secreted alkaline phosphatase (SEAP) in the supernatant of cul-
ture with addition of 0.5 μg of reporter plasmids expressing the
SEAP.
Determination of HBV markers
HBsAg and HBeAg were determined by chemiluminescent enzyme
immunoassay (CLEIA) with commercial kits in a fully automated
Lumipulse CLEIA analyzer (Fujirebio Inc., Tokyo, Japan). HB core-
related antigen (HBcrAg) was measured in serum using the CLEIA
described previously (Kimura et al., 2002). Brieﬂy,150 μL of serumwas
incubated with 150 μL pretreatment solution containing 15% sodium
dodecylsulfate at 60 °C for 30 min. The pretreated serumwas added to
a well coated with three monoclonal antibodies against denatured
HBcAg and HBeAg. After washing, two other alkaline phosphatase-
labelled monoclonal antibodies against denatured HBcAg and HBeAg
were added as secondary antibodies. 200 μL substrate (AMPPD:(3-(2′-
spiroadamantan)-4-methoxy-4- (3′-phosph oryloxy) phenyl-1, 2-
dioxetane disodium salt) (Applied Biosystems, Bedford, MA, USA)
solution was added and the assay tube was incubated for 5 min at
37 °C. HBcrAg assay with the relative chemiluminescence intensitywas measured with chemiluminescent enzyme immunoassay (CLEIA)
system for fully automated Lumipulse f CLEIA analyzer (Fujirebio Inc.,
Tokyo, Japan), and the HBcrAg concentration was estimated by
comparison to a standard curve generated using recombinant
HBeAg. In the present study, the cutoff value was tentatively set at
3.0 log U/mlmL. Sera containing over 7.0 log U/ml mL of HBcrAg were
diluted 10- or 100-fold in normal human serum and re-tested to
obtain the end titer.
Detection and quantiﬁcation of serum HBV DNA
For HBV/G-speciﬁc real-time detection PCR (RTD-PCR), previously
reported set of primers was used, where one of the primers contained
sequence of the HBV/G unique 36-bp insertion (Sugiyama et al.,
2007). For HBV/H DNA quantiﬁcation, following primers were
applied; HBVH29F: 5′-GTT CCA CCA AGC ACT GTT GG-′3, HBV229R:
5′-CGA GTC TAG ACT CTG TGG TAT TGT GAG G-′3. Ampliﬁcation and
detection were performed using SYBR Green PCR Master Mix
(Applied Biosystems) on the ABI Prism 7700 Sequence Detection
System (Applied Biosystems). The quantiﬁcation standard was
prepared by serial dilution of a known amount of the cloned plasmid
of HBV/G or H. The speciﬁcity of these primers was conﬁrmed in
every PCR run by dissociation curve analysis (ABI Prism 7700
dissociation curve software; Applied Biosystems). In assays for HBV
DNA in mouse sera, in which only 10 μL of sample is used, the
sensitivity of the assay allowed detection of 1000 copies/mL of HBV/G
or HBV/H DNA.
Molecular evolutionary analysis
Nucleotide sequences of HBV were aligned by the program
CLUSTAL X, and the genetic distance was estimated with the 6-
parameter method (Gojobori et al., 1982) in the Hepatitis Virus
Database (Robertson et al., 1998). Based on these values, a phyloge-
netic tree was constructed by the neighbor-joining method (Saitou
and Nei, 1987). To conﬁrm the reliability of the phylogenetic tree,
bootstrap resampling test was performed 1,000 times (Felsenstein,
1985).
Examination for recombination
Intergenotypic recombination was searched for using the method
of Robertson et al. (Robertson et al., 1995) with use of the SimPlot
program and bootscanning analysis (Lole et al., 1999). The mean
genetic distances were calculated with a window size of 200 bp and a
step size of 50 bp in this study.
Southern blot hybridizations
Southern blot hybridizations were performed with a full-length
probe of HBV/G or H by previous methods (Fujiwara et al., 2005). No
signiﬁcant differences were observed in the detection between
internal control HBV DNA and each probe.
Inoculation of chimeric mice with the liver repopulated for human
hepatocytes
uPA+/+/SCID+/+ mice with the liver repopulated for human hepa-
tocytes (chimeric mice) were purchased from Phoenix Bio Co., Ltd.
(Hiroshima, Japan). The human hepatocytes were obtained from a
single donor (female, 6 years, African American). Human serum
albumin was measured by ELISA with commercial assay kits (Eiken
Chemical Co.Ltd, Tokyo, Japan). They were inoculated with HBV
recovered from culture supernatants of Huh7 cells transfected with
plasmids containing 1.24-fold HBV genome constructs of the HBV/G or
H (Sugiyama et al., 2006, 2007).
415Y. Tanaka et al. / Virology 376 (2008) 408–415Histopathological examination
Liver tissues were ﬁxed in formaldehyde, embedded in parafﬁn
and stained with hematoxylin–eosin (H–E) or Masson's trichrome.
The ﬁbrosis stage and inﬂammation grade were evaluated by
independent expert pathologists.
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